Related Experiment Video

Updated: Feb 5, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.9K

Genetically engineered cellular membrane-camouflaged nanoparticles amplify immune response against recurrent

Yun Yang1, Qingya Liu2, Meng Pan1

  • 1Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Research Laboratory of Plastic and Burns Surgery, West China Hospital, Sichuan University, Chengdu, 610041, China.

Biomaterials
|February 3, 2026
PubMed

Insights

Researchers developed a novel nanoplatform to combat aggressive triple-negative breast cancer (TNBC). This approach combines metabolic inhibition with immune checkpoint blockade to enhance antitumor immunity and prevent recurrence.

Area of Science:

  • Oncology
  • Immunology
  • Nanotechnology
  • Metabolic Engineering

Background:

  • Cancer progression involves metabolic reprogramming and immune evasion, notably aerobic glycolysis, which supports tumor growth and hinders anti-tumor immunity.
  • Recurrent metastatic triple-negative breast cancer (TNBC) presents a significant clinical challenge, often associated with immune suppression.
  • Aerobic glycolysis fuels cancer cells but also creates an immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

  • To develop a novel biomimetic nanoplatform for treating recurrent metastatic triple-negative breast cancer (TNBC).
  • To investigate the synergistic effects of metabolic inhibition and immune checkpoint blockade in TNBC.
  • To establish a clinically translatable therapeutic strategy for PD-L1-expressing malignancies.

Main Methods:

  • Development of a biomimetic nanoplatform (3BP@CP NPs) using cell-membrane nanovesicles modified with programmed death-1 (PD-1) and encapsulating 3-bromopyruvate (3BP)-loaded nanoparticles.
  • Utilizing 3BP to inhibit hexokinase II (HK2) activity, induce metabolic collapse, and trigger immunogenic cell death.
  • Employing PD-1 modification for targeted tumor homing and programmed death-ligand 1 (PD-L1) checkpoint inhibition.

Main Results:

  • The nanoplatform demonstrated enhanced pharmacokinetics with prolonged circulation and dual PD-L1 targeting.
  • 3BP effectively inhibited HK2, leading to metabolic collapse and reversing TME immunosuppression.
  • The synergistic metabolic-immunological intervention resulted in significant systemic antitumor responses, reduced tumor recurrence and metastasis, and extended survival in TNBC models.

Conclusions:

  • The developed nanoplatform (3BP@CP NPs) offers a promising therapeutic strategy for recurrent metastatic TNBC.
  • Combining metabolic modulators with immune checkpoint inhibition via nanovesicles enhances immunotherapy efficacy.
  • This approach provides a clinically translatable paradigm for treating PD-L1-expressing cancers.
Keywords:
Cellular membrane nanovesiclesGlycolytic inhibitorImmune checkpoint blockadeMetabolic reprogrammingRecurrent metastatic triple-negative breast cancer

More Related Videos

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy05:05

Generating a Murine Orthotopic Metastatic Breast Cancer Model and Performing Murine Radical Mastectomy

Published on: November 29, 2018

11.7K
Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

24.0K

Related Concept Videos

What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
80.2K
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
84.0K
Cellular Membranes and Drug Transport01:24

Cellular Membranes and Drug Transport

Drugs must traverse multiple biological barriers, such as multi-layered skin, single-layered intestinal epithelium, and the plasma membrane, to reach their target sites within the body. The plasma membrane, a highly structured composite of phospholipids, carbohydrates, and proteins, is the cell's protective boundary, facilitating selective substance exchange.
Phospholipids arrange themselves into a bilayer, with hydrophilic heads oriented outward and hydrophobic tails facing inward.
1.5K
Inflammatory Response I: Vascular and Cellular01:30

Inflammatory Response I: Vascular and Cellular

The inflammatory response is the body's defense against infection, injury, or irritation from bacteria, trauma, toxins, or heat. Inflammation helps locate and destroy pathogens and remove damaged tissue elements to heal the body. During this initial phase, fluid, blood products, and nutrients migrate to the injured area, resulting in redness, heat, swelling, ache, and loss of function. Moreover, signs of systemic inflammation include fever, increased WBC count, malaise, anorexia, nausea,...
16.5K
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
84.1K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.9K